The PDLIM5 gene and lithium prophylaxis: An association and gene expression analysis in Sardinian patients with bipolar disorder

Pharmacological Research

Volumn 57, Issue 5, 2008, Pages 369-373

  Squassina, Alessio ^a   Congiu, Donatella ^a   Manconi, Francesca ^a   Manchia, Mirko ^a   Chillotti, Caterina ^a   Lampus, Simona ^a   Severino, Giovanni ^a   Zompo, Maria Del ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Bipolar disorder; Lithium therapy; PDLIM5 expression; Sardinia

Indexed keywords

ADAPTOR PROTEIN; LITHIUM; PROTEIN PDLIM5;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; LYMPHOBLASTOID CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN INTERACTION; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; BIPOLAR DISORDER; FEMALE; GENE EXPRESSION; HUMANS; ITALY; LITHIUM; LYMPHOCYTES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN KINASE C-EPSILON; SIGNAL TRANSDUCTION;

EID: 44549084061     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.03.011     Document Type: Article

References (53)

1. Goodwin F.K., and Jamison K.R. Manic-depressive illness (1990), Oxford University Press, New York
2. Shou M. Origin, prevention and treatment of affective disorders (1979), Academic Press, London
3. Gershon S., and Soares J.C. Current therapeutic profile of lithium. Arch Gen Psychiatry 54 (1997) 16-20
4. Price L.H., and Heninger G.R. Lithium in the treatment of mood disorders. N Engl J Med 331 (1994) 591-598
5. Quiroz J.A., Gould T.D., and Manji H.K. Molecular effects of lithium. Mol Interv 4 (2004) 259-272
6. Brunello N., and Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int J Neuropsychopharmacol 6 (2003) 181-189
7. LinksLenox R.H., McNamara R.K., Papke R.L., and Manji H.K. Neurobiology of lithium: an update. J Clin Psychiatry 59 (1998) 37-47
8. Zatz M., and Reisine T.D. Lithium induces corticotropin secretion and de-sensitization in cultured anterior pituitary cells. Proc Natl Acad Sci 82 (1985) 1286-1290
9. Reisine T., and Zatz M. Interactions between lithium, calcium, diacylglycerides and phorbol esters in the regulation of ACTH release from AtT-20 cells. J Neurochem 49 (1987) 884-889
10. Wang H.Y., and Friedman E. Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology 99 (1989) 213-218
11. Casebolt T.L., and Jope R.S. Effects of chronic lithium treatment on protein kinase C and cyclic AMP-dependent protein phosphorylation. Biol Psychiatry 29 (1991) 233-243
12. Lenox R.H., Watson D.G., Patel J., and Ellis J. Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 570 (1992) 333-340
13. Manji H.K., Etcheberrigaray R., Chen G., and Olds J.L. Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the a isozyme. J Neurochem 61 (1993) 2303-2310
14. Jensen J.B., and Mork A. Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol 7 (1997) 173-179
15. Chen G., Masana M.I., and Manji H.K. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2 (2000) 217-236
16. Hahn C.G., Umapathy, Wang H.Y., Koneru R., Levinson D.F., and Friedman E. Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res 39 (2005) 355-363
17. 2+ channels and synaptic transmission. Nature 361 (1993) 165-168
18. 2+ channels. Nat Neurosci 6 (2003) 468-475
19. 2+ channel complex. Cell Signal. 18 (2006) 215-224
20. Dubovsky S.L., Murphy J., Thomas M., and Rademacher J. Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am J Psychiatry 149 (1992) 118-120
21. Emamghoreishi M., Schlichter L., Li P., Parikh S., Sen J., Kamble A., et al. High intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry 154 (1997) 976-982
22. 2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder. Int J Neuropsychopharmacol 6 (2003) 379-389
23. Dubovsky S.L., Christiano J., Daniell L.C., Franks R.D., Murphy J., Adler L., et al. Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Arch Gen Psychiatry 46 (1989) 632-638
24. Tan C.H., Javors M.A., Seleshi E., Lowrimore P.A., and Bowden C.L. Effects of lithium on platelet ionic intracellular calcium concentration in patients with bipolar (manic-depressive) disorder and healthy controls. Life Sci 46 (1990) 1175-1180
25. Hough C., Lu S.J., Davis C.L., Chuang D.M., and Post R.M. Elevated basal and thapsigargin-stimulated intracellular calcium of platelets and lymphocytes from bipolar affective disorder patients measured by a fluorometric microassay. Biol Psychiatry 46 (1999) 247-255
26. Hallcher L.M., and Sherman WR. The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J Biol Chem 255 (1980) 10896-10901
27. Manji H.K., Bersudsky Y., Chen G., Belmaker R.H., and Potter W.Z. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 15 (1996) 370-381
28. Li X., Bijur G.N., and Jope R.S. Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4 (2002) 137-144
29. Steen V.M., Løvlie R., Osher Y., Belmaker R.H., Berle J.O., and Gulbrandsen A.K. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 8 (1998) 259-268
30. Serretti A., Lilli R., Lorenzi C., Franchini L., and Smeraldi E. Dopamine receptor D3 gene and response to lithium prophylaxis in mood disorders. Int J Neuropsychopharmacol 1 (1998) 125-129
31. Serretti A., Lilli R., Mandelli L., Lorenzi C., and Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 1 (2001) 71-77
32. Serretti A., Malitas P.N., Mandelli L., Lorenzi C., Ploia C., Alevizos B., et al. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders. Pharmacogenomics J 4 (2004) 267-273
33. Benedetti F., Serretti A., Pontiggia A., Bernasconi A., Lorenzi C., Colombo C., et al. Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta-50 T/C SNP. Neurosci Lett 376 1 (2005 Mar 7) 51-55
34. Iwamoto K., Kakiuchi C., Bundo M., Ikeda K., and Kato T. Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 9 (2004) 406-416
35. Iwamoto K., Bundo M., Washizuka S., Kakiuchi C., and Kato T. Expression of HSPF1 and LIM in the lymphoblastoid cells derived from patients with bipolar disorder and schizophrenia. J Hum Genet 49 (2004) 227-231
36. Kato T., Iwayama Y., Kakiuchi C., Iwamoto K., Yamada K., Minabe Y., et al. Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia. Mol Psychiatry 10 (2005) 1045-1065
37. Squassina A, Manchia M, Manconi F, Piccardi MP, Ardau R, Chillotti C, et al. A case-control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatr Genet 2008, 18, doi:10.1097/YPG.0b013e3282fb003d.
38. Endicott J., and Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35 (1978) 837-844
39. Post R.M., Roy-Byrne P.P., and Uhde T.W. Graphic representation of the life course of illness in patients with affective disorder. Am J Psychiatry 145 (1988) 844-848
40. Grof P., Duffy A., Cavazzoni P., Grof E., Garnham J., MacDougall M., et al. Is response to prophylactic lithium a familial trait?. J Clin Psychiatry 63 (2002) 942-947
41. Lahiri D.K., and Nurnberger Jr. J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19 (1991) 5444
42. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 73 (1986) 320-326
43. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
44. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25 (2003) 115-121
45. Turecki G., Grof P., Cavazzoni P., Duffy A., Grof E., Ahrens B., et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 3 (1998) 534-538
46. Michelon L., Meira-Lima I., Cordeiro Q., Miguita K., Breen G., Collier D., et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 403 (2006) 288-293
47. Løvlie R., Berle J.O., Stordal E., and Steen V.M. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet 11 (2001) 41-43
48. Arcos-Burgos M., and Muenke M. Genetics of population isolates. Clin Genet 61 (2002) 233-247
49. Peltonen L., Palotie A., and Lange K. Use of population isolates for mapping complex traits. Nat Rev Genet 1 (2000) 182-190
50. Abbot A. Manhattan versus Reykjavik. Nature 406 (2000) 340-342
51. Alda M. Pharmacogenetics of lithium response in bipolar disorder. J Psychiatry Neurosci 24 (1999) 154-158
52. Mamdani F., Groisman I.J., Alda M., and Turecki G. Pharmacogenetics and bipolar disorder. Pharmacogenomics J 4 (2004) 161-170
53. Horiuchi Y., Arai M., Niizato K., Iritani S., Noguchi E., Ohtsuki T., et al. A polymorphism in the PDLIM5 gene associated with gene expression and schizophrenia. Biol Psychiatry 59 (2006) 434-439